Repository logo
  • English
  • 中文
Log In
Have you forgotten your password?
  1. Home
  2. College of Medicine / 醫學院
  3. School of Medicine / 醫學系
  4. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial
 
  • Details

Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial

Journal
British Journal of Dermatology
Journal Volume
178
Journal Issue
1
Pages
114-123
Date Issued
2018
Author(s)
Langley R.G.
TSEN-FANG TSAI  
Flavin S.
Song M.
Randazzo B.
Wasfi Y.
Jiang J.
Li S.
Puig L.
DOI
10.1111/bjd.15750
URI
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85028508389&doi=10.1111%2fbjd.15750&partnerID=40&md5=b5b0248a4dedcbdb8223eab869d6b6a4
https://scholars.lib.ntu.edu.tw/handle/123456789/517569
Abstract
Background: Guselkumab, an anti-interleukin-23 monoclonal antibody, has demonstrated significant efficacy in phase III psoriasis trials. Objectives: To evaluate the efficacy and safety of guselkumab in patients with moderate-to-severe plaque psoriasis who had an inadequate response to ustekinumab. Methods: In this phase III, randomized, double-blind study, 871 patients received open-label ustekinumab (45?mg or 90?mg) at weeks 0 and 4. At week 16, 268 patients with an inadequate response to ustekinumab [Investigator's Global Assessment (IGA) ??2] were randomized (double-blind) to guselkumab 100?mg or to continue ustekinumab; 585 of 871 patients (67%) with IGA 0/1 at week 16 continued open-label ustekinumab. The primary end point was the number of visits at which randomized patients achieved IGA 0/1 and at least a two-grade improvement (from week 16) from week 28 to week 40. Improvement ??90% or 100% in Psoriasis Area and Severity Index (PASI 90/100) and Dermatology Life Quality Index (DLQI) of 0/1 were also assessed. Results: The mean number of visits at which patients achieved IGA 0/1 and at least a two-grade improvemen (week 28–40) was significantly greater in the guselkumab group vs. the randomized ustekinumab group (1·5 vs. 0·7; P?
SDGs

[SDGs]SDG3

Other Subjects
adalimumab; apremilast; cyclosporine; etanercept; etretin; guselkumab; infliximab; methotrexate; tofacitinib; ustekinumab; biological product; dermatological agent; guselkumab; monoclonal antibody; ustekinumab; abscess; adult; appendicitis; Article; backache; bacterial arthritis; basal cell carcinoma; bile duct cancer; connective tissue disease; controlled study; Dermatology Life Quality Index; double blind procedure; drug efficacy; drug response; drug safety; drug treatment failure; drug withdrawal; epididymitis; female; heart infarction; human; immunogenicity; infection; injection site reaction; major clinical study; male; multicenter study; musculoskeletal disease; open study; pancreas carcinoma; periodontitis; phase 3 clinical trial; priority journal; Psoriasis Area and Severity Index; psoriasis vulgaris; psoriatic arthritis; PUVA; randomized controlled trial; rhinopharyngitis; salpingitis; squamous cell skin carcinoma; transitional cell carcinoma; upper respiratory tract infection; urinary tract infection; clinical trial; patient-reported outcome; psoriasis; treatment outcome; Adult; Antibodies, Monoclonal; Biological Products; Dermatologic Agents; Double-Blind Method; Female; Humans; Male; Patient Reported Outcome Measures; Psoriasis; Treatment Outcome; Ustekinumab
Publisher
Blackwell Publishing Ltd
Type
journal article

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Open policy finder網站查詢,以確認出版單位之版權政策。
    Please use Open policy finder to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science